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a reduction in medication. The patients who ex‑
perienced the most deprescribing were those who 
had ADRs, recent falls, and diabetic patients with 
episodes of hypoglycemia. From a wide range of 
predictive factors, the number of drugs on admis‑
sion, the number of comorbid conditions, age, 
solitary living status, and incident ADRs were 
the factors that in a multiple logistic regression 
model accounted for the significant deprescribing 
in these patients. Low body mass index also had 
a positive influence: the lower the BMI, the great‑
er the degree of deprescribing by the attending 
physicians. The authors conclude that in ‑patient 
specialist geriatric assessment achieved signifi‑
cant deprescribing. Because of the retrospective 
nature of the study, it was not possible to deter‑
mine what (if any) effect the deprescribing had 
on patients’ cognition or physical function or 
quality of life.
The findings of Bień and Bień ‑Barkowska2 may 
not be surprising. Specialist geriatricians are 
trained to examine multimorbid older patients’ 
medication lists carefully, given that polyphar‑
macy engenders inappropriate prescribing and 
ADRs or ADEs.3 Deprescribing in specialist geri‑
atric medical units arises through careful med‑
ication review, which has always been an inte‑
gral part of comprehensive geriatric assessment, 
the cornerstone of specialist geriatric medical 
practice. Careful medication review and optimi‑
zation in the context of comprehensive geriatric 
assessment (or “geriatric evaluation and manage‑
ment” in the study by Bień and Bień‑Barkowska) 
in turn depends on specialist training and wide 
knowledge of drug ‑related problems in old age as 
well as the various and often nonspecific manifes‑
tations of ADRs and ADEs in older people. Ger‑
iatricians will also be keenly aware of “prescrib‑
ing cascades”, that is inappropriate prescribing 
of new medication for presenting symptoms in 
multimorbid older people that are misinterpret‑
ed as symptoms of new medical conditions in 
these patients. For example, an older person with 
Polypharmacy in older people presents a real 
threat to the health and welfare of older people 
globally, because of the close cause ‑and ‑effect 
relationship with inappropriate prescribing and 
adverse drug reactions (ADRs) and adverse drug 
events (ADEs). Given the phenomenon of pop‑
ulation aging both in developed and developing 
countries, it is clear that the heightened risk of 
ADRs and ADEs from polypharmacy represents 
a major global public health problem.
Polypharmacy is traditionally defined (some‑
what arbitrarily) as the intake of 5 or more daily 
drugs, with major polypharmacy usually meaning 
consumption of 10 or more daily drugs. The cause 
of polypharmacy in old age is clearly multimorbid 
illness, that is, more chronic medical conditions 
leading to more drugs being prescribed.1 The diffi‑
culty is that the risk of ADRs or ADEs rises in par‑
allel with increasing medication, so that the risk 
of an older person experiencing drug adversity of 
one kind or another when taking 10 daily drugs is 
about 100%. It is therefore in older patients’ best 
interest to restrict the number of daily drugs they 
are prescribed. The difficulty for prescribers is that 
there is no agreed “safe limit” for the number of 
daily drugs. Most prescribers appreciate that it is 
very easy to add more drugs to the prescription 
of older persons with multimorbidity; it is much 
more difficult to remove drugs (or “deprescribe”) 
from their prescription list.
In the  present issue of this journal, Bień 
and Bień‑Barkowska2 retrospectively examine 
the changes in the prescriptions of 301 older 
people from admission to discharge from a spe‑
cialist geriatric medicine unit in one hospital 
in Białystok, Poland. The mean age of the pa‑
tients was 82.4 years and two ‑thirds were fe‑
male, as expected for a geriatric hospital co‑
hort such as this. They found a significant re‑
duction in the number of drugs prescribed per 
patient from admission (average 7.53 drugs per 
patient) to discharge (average 6.25 drugs per pa‑
tient) and that 57% of the patients experienced 
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The challenge now facing researchers in this 
area is how to implement PIM criteria in the rou‑
tine clinical care of older patients with polyphar‑
macy. Researchers generally agree that meeting 
this challenge depends on sufficiently robust soft‑
ware to apply PIM criteria and to present the rel‑
evant PIM criteria that apply to individual pa‑
tients to their physicians accurately and quick‑
ly. To this end, 2 important RCTs have recently 
been funded by the European Commission: SEN‑
ATOR10 and OPERAM.11 The software interven‑
tions tested in these trials are based primarily on 
STOPP/START version 2 criteria.5 The SENATOR 
trial has been completed this year and OPERAM 
is expected to finish randomization later in 2018. 
SENATOR has randomized over 1500 patients to 
standard pharmaceutical or once ‑off software‑
‑driven application of STOPP/START criteria as 
well as drug‑drug and drug‑disease interactions. 
OPERAM is expected to randomize over 1800 pa‑
tients in a cluster randomized design to standard 
pharmaceutical care or single ‑time point applica‑
tion of STOPP/START criteria using a different 
software engine. These multicenter trials will de‑
termine whether software ‑driven deprescribing 
reduces ADRs (SENATOR) and drug ‑related un‑
scheduled hospitalizations (OPERAM).
Are there any practical guidelines to help phy‑
sicians deprescribe drugs effectively and safely, 
specifically in very frail older multimorbid pa‑
tients with poor survival prognosis who repre‑
sent a very important and growing population of 
older people globally? In these patients, the fo‑
cus of pharmacotherapy should be on symptom 
relief as distinct from long ‑term primary or sec‑
ondary disease prevention. In this context, drugs 
that would be generally appropriate (eg, statins, 
calcium supplements) become potentially futile. 
Scott et al12 have recently proposed a protocol for 
assessing individual medications in older people 
burdened by polypharmacy. A follow ‑up small‑
‑scale open ‑label study of 50 older multimor‑
bid patients (mean age, 82.5 years) by the same 
group showed that a median number of 10 med‑
ications at hospital admission could be reduced 
to a median of 7 medications at discharge, with 
less than 2% of deprescribed drugs needing to 
be represcribed at follow ‑up (median, 78 days).13 
A small ‑scale RCT involving 47 older interven‑
tion patients and 48 control patients in 4 nurs‑
ing homes in Western Australia using the same 
deprescribing algorithm showed a mean (SD) re‑
duction of 1.9 (4.1) drugs per patient compared 
with a slight mean (SD) increase of +0.1 (3.5) 
drugs in the control group at 1 ‑year follow ‑up.14 
In contrast to the implicit deprescribing algo‑
rithm of Scott et al12 are the recently published 
27 explicit deprescribing STOPPFrail criteria.15 
An RCT involving STOPPFrail criteria as the in‑
tervention compared with standard pharmaceu‑
tical care in frail, multimorbid older people with 
poor survival prognosis is being conducted in our 
center. While the results of all these clinical tri‑
als are awaited, physicians should nevertheless 
dementia who receives a neuroleptic antipsychot‑
ic for night ‑time agitation develops parkinson‑
ism. The patient is referred to another physician 
regarding the parkinsonism and is subsequently 
commenced on levodopa. The patient becomes 
hypotensive on levodopa and subsequently suf‑
fers a fracture injury due to a syncopal fall re‑
lating to inappropriately prescribed levodopa.
Several explicit potentially inappropriate med‑
ication (PIM) lists exist in the literature that were 
designed specifically for the growing older per‑
son population. The most commonly cited among 
the explicit PIM lists are Beers criteria (now in 
its 5th iteration4) and STOPP criteria (now in its 
2nd iteration5). There are also several implicit 
PIM lists designed for the geriatric population, 
most notably ACOVE criteria and the Medica‑
tion Appropriateness Index. Although implic‑
it PIM criteria sets are undoubtedly useful as 
research tools, none has entered routine clini‑
cal practice as a deprescribing tool, probably be‑
cause they are too time ‑consuming to deploy. In 
contrast, Beers criteria and STOPP criteria are 
now used in several countries as routine medi‑
cation review tools. Beers criteria have been en‑
dorsed by the American Geriatrics Society for 
several years. STOPP criteria are recommend‑
ed in the recent UK National Institute for Clini‑
cal Excellence guidelines for structured medica‑
tion review in older people with polypharmacy 
as a practical means of deprescribing (https://
www.nice.org.uk/guidance/ng5).
Despite the multiplicity of explicit deprescrib‑
ing criteria sets, few randomized clinical trials 
(RCTs) exist in which deprescribing criteria have 
been used as an intervention and compared with 
standard pharmaceutical care. Only STOPP crite‑
ria have been tested by an RCT; currently, there 
are 3 RCTs involving STOPP in the hospital set‑
ting and 1 RCT in a large nursing home facili‑
ty. All 4 RCTs are single ‑center and none was 
double ‑blinded. Two of these RCTs took place in 
our center; the primary outcomes in these RCTs 
were medication appropriateness and incident 
ADRs, respectively.6,7 The total average number of 
drugs per patient was not significantly reduced in 
the intervention groups compared with controls 
in these 2 trials, most probably because what‑
ever deprescribing was achieved through appli‑
cation of STOPP criteria was likely counterbal‑
anced by addition of new medications through 
application of START criteria. In the RCT report‑
ed by Frankenthal et al,8 undertaken in 359 frail 
nursing home residents in Israel, application of 
STOPP/START criteria did achieve significant re‑
duction in the number of daily drugs in the inter‑
vention cohort (mean [SD], 8.1 [3.2]) compared 
with the control cohort (mean [SD], 9.0 [3.3]). 
Although the proportion of intervention patients 
with PIMs at hospital discharge was significant‑
ly less than controls in the RCT by Dalleur et al,9 
the impact of STOPP/START criteria on the av‑
erage number of daily medications in the inter‑
vention cohort was not documented.
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seek to deprescribe medication in frail multimor‑
bid older people.
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